Overview
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
Description
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine. Up to 20 participants per cohort will be invited.
Eligibility
Inclusion Criteria:
- Completion of study GPNV-001 as per protocol with no significant deviations.
- Has provided written informed consent.
Exclusion Criteria:
- Potential participants will be excluded if they have received a pneumococcal vaccine since the end of study visit for study GPNV-001
- A potential participant has had an episode of pneumonia since completing Study GPNV-001